About Black Diamond Therapeutics

Our Vision:

Precision Cancer Medicines for Every Genetically Defined Patient

Black Diamond Therapeutics: A Precision Oncology Medicine Company Pioneering the Discovery of Small Molecule, MasterKey Therapies

Black Diamond targets undrugged mutations in patients with genetically defined cancers for whom limited treatment options currently exist. Black Diamond is built upon a deep understanding of cancer genetics, protein structure and function, and medicinal chemistry.

The Company’s proprietary Mutation-Allostery-Pharmacology, or MAP, drug discovery platform, is designed to allow Black Diamond to analyze population-level genetic sequencing data to identify oncogenic mutations that promote cancer across tumor types, group these mutations into families and develop a single small molecule therapy that targets a specific family of mutations, termed a MasterKey therapy.

Black Diamond was founded by David M. Epstein, Ph.D., and Elizabeth Buck, Ph.D., and starting in 2017, together with Versant Ventures, began building its MAP platform and chemistry discovery engine. Black Diamond was the first company to emerge from Versant’s Ridgeline Discovery Engine in Basel, Switzerland. Versant’s Ridgeline team of scientists, including Alex Mayweg, Ph.D., Fang Ni, Pharm.D, Alexander Flohr, Ph.D., Roberto Iacone, Ph.D., Giorgio Ottaviani, Ph.D., DABT, along with Black Diamond scientist Matthew O’Connor, were instrumental in helping us define our drug discovery strategies, identify our initial core programs, develop our lead candidate BDTX-189, and validate our MAP platform.

The cornerstone of our approach derives from evolving trends in targeted oncology therapies. Genetic sequencing of cancers has become increasingly widespread, leading to the discovery of multiple genetic alterations which were previously unaddressed, unsuccessfully targeted or overlooked. Today, new baskets of undrugged oncogenic targets have been identified, revealing a significant unmet medical need for novel targeted therapies that can extend precision medicines to patients with cancer.